Patrick Vallance

Patrick Vallance
Name	Patrick Vallance
Birth date	1960
Nationality	British
Occupation	Clinical pharmacologist, physician, scientist, civil servant
Known for	Chief Scientific Adviser to the United Kingdom government; work on signal transduction, drug discovery

Patrick Vallance is a British clinical pharmacologist and physician who served as the United Kingdom’s Chief Scientific Adviser and Head of the Government Office for Science. He combined academic research in signal transduction and vascular biology with senior executive roles in the pharmaceutical industry before entering public service. Vallance became a prominent public figure during the COVID-19 pandemic and has been associated with science-policy interfaces across multiple universities, research councils, and international health bodies.

Early life and education

Vallance was born in 1960 and educated in the United Kingdom. He read medicine at University College London and trained clinically at University College Hospital, where he qualified in medicine and developed an early interest in clinical pharmacology and translational medicine. He undertook doctoral research leading to a PhD at University College London with a focus on vascular biology and endothelial function, working alongside researchers affiliated with Medical Research Council units and collaborating with colleagues from Imperial College London and King's College London.

Medical and research career

Vallance trained and practiced as a physician in the NHS clinical environment, holding posts at St Thomas' Hospital and contributing to clinical pharmacology services. In academia he established a research programme on endothelial cell biology, nitric oxide signalling and the regulation of vascular tone, publishing in journals frequented by investigators from Wellcome Trust, Nature Medicine, The Lancet, and Science Translational Medicine. His laboratory collaborated with teams at Wellcome Centre for Human Genetics, Francis Crick Institute, MRC Laboratory of Molecular Biology, and international groups at Harvard Medical School and Massachusetts General Hospital on mechanisms of vasodilation and platelet biology. He supervised doctoral students who later joined institutions such as University of Cambridge and University of Oxford.

Pharmaceutical industry and GlaxoSmithKline

Transitioning to industry, Vallance joined GlaxoSmithKline (GSK), where he rose to senior leadership in research and development. At GSK he was involved in small-molecule drug discovery, target validation and translational science, interacting with regulatory bodies including the European Medicines Agency and the Medicines and Healthcare products Regulatory Agency. He held responsibilities that required coordination with business units, academic partners such as University of California, San Francisco and Johns Hopkins University, and biotech collaborators from Genentech and Amgen. His tenure encompassed strategic decisions on portfolios spanning cardiovascular, respiratory and oncology pipelines, and he represented industry in consortia with the Innovative Medicines Initiative and public-private partnerships linked to Bill & Melinda Gates Foundation funding.

Government service and Chief Scientific Adviser

In 2018 Vallance was appointed Chief Scientific Adviser (CSA) to the United Kingdom government and Head of the Government Office for Science. In this role he provided scientific advice to cabinets and ministers across departments including the Department of Health and Social Care, Home Office, and Ministry of Defence, liaised with agencies such as Public Health England and the National Health Service, and engaged with international science diplomacy through World Health Organization and G7 scientific channels. He worked with funding organisations including the Medical Research Council, UK Research and Innovation, and charities such as the Wellcome Trust to align research priorities and evidence syntheses for policy.

COVID-19 pandemic role and controversies

During the COVID-19 pandemic Vallance became a senior public-facing scientific adviser, appearing alongside governmental ministers, officials from NHS England, and public health leaders from Public Health England and SAGE (Scientific Advisory Group for Emergencies). He engaged with modelling teams from Imperial College London and epidemiologists linked to London School of Hygiene & Tropical Medicine to interpret projections for policymakers. His prior industry role at GlaxoSmithKline prompted scrutiny and debate about conflicts of interest raised by media outlets such as The Guardian and BBC News, and by parliamentary committees including the House of Commons Science and Technology Committee. Controversies also centred on the timing and communication of non-pharmaceutical interventions, the use of epidemiological models from Neil Ferguson’s group, and the balance between scientific advice and ministerial decisions in televised briefings.

Honours, awards and memberships

Vallance has received honours and professional recognition, including election to fellowships at institutions such as the Academy of Medical Sciences and membership of advisory boards linked to the Royal Society. He has been awarded honours by the United Kingdom government and been invited to speak at venues including the Royal Society and the Wellcome Collection. He has served on editorial boards for journals associated with American Society for Clinical Investigation and participated in collaborative initiatives with organisations such as Coalition for Epidemic Preparedness Innovations and the European Respiratory Society.

Personal life and interests

Vallance lives in the United Kingdom and is married with family. Outside professional commitments he has taken an interest in scientific communication, public engagement at institutions like the Natural History Museum and Science Museum, and activities supportive of biomedical research charities including Cancer Research UK and British Heart Foundation. He has participated in lecture series at King’s College London and contributed to policy forums hosted by think tanks such as Chatham House and Institute for Government.

Category:British physicians Category:Clinical pharmacologists Category:Chief Scientific Advisers to the United Kingdom government